The Beachbody Company, Inc. Announces Transfer of Stock Exchange Listing to Nasdaq
'Our move to Nasdaq will allow us to leverage their advanced trading technology and market data services to better serve our shareholders. As we continue to successfully execute against our strategic transformation, we're excited to join a community of the world's most dynamic companies on an exchange that shares our commitment to innovation,' commented Carl Daikeler, BODi's co-founder and Chief Executive Officer.
'Nasdaq has established itself as the premier destination for innovative game-changers that are reshaping their industries, disrupting traditional business models and creating new market opportunities. This move aligns BODi with a marketplace that values and supports transformative companies like ours,' said Mark Goldston, Executive Chairman of BODi.
About BODi and The Beachbody Company, Inc.
Originally known as Beachbody, BODi has been innovating structured step-by-step home fitness and nutrition programs for 25 years such as P90X, Insanity, and 21-Day Fix, plus the first premium superfood nutrition supplement, Shakeology. Since its inception in 1999 BODi has helped over 30 million customers pursue extraordinary life-changing results. The BODi community represents millions of people helping each other stay accountable to goals of healthy weight loss, improved strength and energy, and resilient mental and physical well-being. For more information, please visit TheBeachBodyCompany.com.
Forward-Looking Statements
This press release of The Beachbody Company, Inc. ('we,' 'us,' 'our,' and similar terms) contains 'forward-looking' statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are statements other than statements of historical facts and statements in future tense, including statements regarding the commencement of trading of our Class A common stock on the Nasdaq Capital Market.
Forward-looking statements are based upon various estimates and assumptions, as well as information known to us as of the date hereof, and are subject to risks and uncertainties. Accordingly, actual results could differ materially due to a variety of factors, including: our ability to effectively compete in the fitness and nutrition industries; our ability to successfully acquire and integrate new operations; our reliance on a few key products; market conditions and global and economic factors beyond our control; intense competition and competitive pressures from other companies worldwide in the industries in which we operate; litigation and the ability to adequately protect our intellectual property rights; and the successful transfer of the listing of our Class A common stock on the Nasdaq. You can identify these statements by the use of terminology such as 'believe', 'plans', 'expect', 'will', 'should,' 'could', 'estimate', 'anticipate' or similar forward-looking terms. You should not rely on these forward-looking statements as they involve risks and uncertainties that may cause actual results to vary materially from the forward-looking statements. For more information regarding the risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forward-looking statements, as well as risks relating to our business in general, we refer you to the 'Risk Factors' section of our Securities and Exchange Commission filings, including those risks and uncertainties included in the Form 10-K filed with the SEC on March 28, 2025 and any subsequent Quarterly Reports on Form 10-Q or Current Reports on Form 8-K, which are available on the Investor Relations page of our website at https://investors.thebeachbodycompany.com and on the SEC website at www.sec.gov.
All forward-looking statements contained herein are based on information available to us as of the date hereof and you should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance, or achievements. We undertake no obligation to update any of these forward-looking statements for any reason after the date of this press release or to conform these statements to actual results or revised expectations, except as required by law. Undue reliance should not be placed on forward-looking statements.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Plymouth Rises 47% on Receiving Acquisition Proposal From Sixth Street
Plymouth Industrial REIT PLYM recently announced that it has received an unsolicited, non-binding proposal from Sixth Street Partners, LLC, aimed at acquiring all of the outstanding shares of the company's common stock for a cash consideration of $24.10 per share. Shares of this industrial REIT witnessed a 47.06% rise in the regular trading session on the NYSE on Tuesday, following the announcement. As per the Schedule 13D filed with the U.S. Securities and Exchange Commission, which discloses the proposal, Sixth Street beneficially owns approximately 9.99% of Plymouth's outstanding common stock. In accordance with its fiduciary duties and following consultations with its financial and legal advisors, the company's board of directors will thoroughly review the proposal to ascertain the course of action that it considers to be in the best interests of all Plymouth shareholders. The company, which focuses on the acquisition, ownership and management of single- and multi-tenant industrial properties, noted that shareholders are not required to take any action at this time. Plymouth, with its opportunistic acquisitions and healthy leasing activity, is well-positioned to benefit. However, macroeconomic uncertainties and tariff issues remain a major concern in the near term. In the past three months, shares of this Zacks Rank #2 (Buy) company have rallied 36.7% against the industry's decline of 0.1%. Image Source: Zacks Investment Research Other Stocks to Consider Some other top-ranked stocks from the broader REIT sector are Host Hotels & Resorts HST and Welltower WELL, each carrying a Zacks Rank #2 at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate for HST's 2025 FFO per share has moved 4 cents northward to $1.95 over the past month. The Zacks Consensus Estimate for WELL's 2025 FFO per share has moved 2 cents upward to $5.06 over the past week. Note: Anything related to earnings presented in this write-up represents funds from operations (FFO), a widely used metric to gauge the performance of REITs. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Host Hotels & Resorts, Inc. (HST) : Free Stock Analysis Report Plymouth Industrial REIT (PLYM) : Free Stock Analysis Report Welltower Inc. (WELL) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
40 minutes ago
- Yahoo
Is Pfizer's 6.8%-Yielding Dividend Too Good to Be True?
Key Points Pfizer's payout ratio is around 90% of earnings, which is high for a dividend stock. It reported strong operational growth of 10% in its most recent quarter. The company continues to focus on cutting costs to improve overall profitability. 10 stocks we like better than Pfizer › Finding a high-yielding stock that is safe to hang on to can be a rarity. When yields get high (e.g., more than 5%), usually there's a reason behind it. And investors are often hesitant to invest in such stocks, fearing that those incredibly attractive payouts may not end up being sustainable. One of the highest yields you can get right now is from Pfizer (NYSE: PFE). The healthcare giant offers a yield of 6.8%, which is more than five times what the average rate is for the typical stock on the S&P 500 -- just 1.2%. Could Pfizer be one of the best dividend stocks to add to your portfolio right now, or is its yield too good to be true? Is Pfizer's high payout ratio a concern? A common metric to rely on when evaluating the safety of a dividend stock is its payout ratio. This tells you how much of a company's earnings are being paid out in the form of dividends. The higher it is, the more unsustainable the payout potentially is. Pfizer's payout ratio is currently around 90%, which suggests there isn't a big buffer in its bottom line. However, that number is skewed due to Pfizer's year-end results. In the last three months of 2024, the company incurred billions in asset impairment charges, restructuring expenses, and other non-cash items, which weighed down its earnings. And since the payout ratio looks at a company's earnings over the past 12 months, all it takes is one bad quarter to weigh it down. This is where relying on cash flow can be a better indicator of how healthy a dividend really is. In the trailing 12 months, Pfizer's free cash flow totaled $12.4 billion, which is far higher than the $9.6 billion it paid out in dividends over the past year. This implies the dividend is indeed safe. Recent results suggest the company is going in the right direction As of the end of last week, Pfizer's stock price is down 5% year to date, despite it already taking a beating in previous years. Investors remain concerned about not only its dividend, but also its growth potential. Pfizer is working to reduce costs while also growing its operations. Acquisitions, including its massive $43 billion purchase of oncology company Seagen in 2023, opened up new doors and opportunities for the business that look to be paying off. In its most recent quarter, which ended on June 29, the company reported year-over-year revenue growth of 10%, with sales topping $14.7 billion. Meanwhile, the company continues to reduce costs as it adapts to declining demand for its COVID-19 vaccine and pill. Its diluted earnings per share this past quarter totaled $0.51 -- higher than the rate of its quarterly dividend payment ($0.43). Pfizer's dividend looks safe, and the stock still looks cheap From looking at its financials, there aren't any glaring concerns to suggest that Pfizer's dividend is in trouble. I believe investors are being overly cautious with the stock. And with Pfizer focusing on cost reduction while also still growing its business, it's a top income-generating investment you can own for the long haul. It's currently trading at a price-to-earnings multiple of just 13, making it a fairly cheap stock to own. There are risks for many healthcare companies these days as healthcare reform may impact future profitability, but that can be difficult to predict and forecast. Pfizer is doing an excellent job of managing what it can control, and it's among the best stocks to buy in the healthcare sector. Should you buy stock in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. Is Pfizer's 6.8%-Yielding Dividend Too Good to Be True? was originally published by The Motley Fool
Yahoo
40 minutes ago
- Yahoo
Jim Cramer Calls Cisco a 'Great Company With Great Management'
Cisco Systems, Inc. (NASDAQ:CSCO) is one of the stocks Jim Cramer talked about. Cramer said that he has been 'paying close attention' to the company stock. He commented: 'Now, I've been paying close attention to this one because Cisco's the newest holding for my Charitable Trust. We bought it late last month, and it had a quick 3% gain going into yesterday's close. Today, though, we have a smaller gain, but even though the quarter wasn't perfect, I think it was net positive… Ken Wolter / Cisco Systems, Inc. (NASDAQ:CSCO) designs and sells networking hardware, software, and security solutions that enable connectivity across data centers, enterprises, and wireless networks. While we acknowledge the potential of CSCO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
